{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:13:24Z","timestamp":1787958804319,"version":"build-2784847793"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01218-1","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:44:59Z","timestamp":1778312699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Precision oncology in gastric cancer: navigating molecular subtypes, therapeutic targets, and future horizons"],"prefix":"10.1007","volume":"49","author":[{"given":"Yanyun","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"1218_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021). https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J. Clin."},{"key":"1218_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"E.C. Smyth, M. Nilsson, H.I. Grabsch, van N.C. Grieken, F. Lordick, Gastric cancer. Lancet. 396, 635\u2013648 (2020). https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5","journal-title":"Lancet"},{"key":"1218_CR3","doi-asserted-by":"publisher","first-page":"101404","DOI":"10.1016\/j.eclinm.2022.101404","volume":"47","author":"E Morgan","year":"2022","unstructured":"E. Morgan, M. Arnold, M.C. Camargo, A. Gini, A.T. Kunzmann, T. Matsuda et al., The current and future incidence and mortality of gastric cancer in 185 countries, 2020\u201340: a population-based modelling study. EClinicalmedicine. 47, 101404 (2022). https:\/\/doi.org\/10.1016\/j.eclinm.2022.101404","journal-title":"EClinicalmedicine"},{"key":"1218_CR4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"F. Lordick, F. Carneiro, S. Cascinu, T. Fleitas, K. Haustermans, G. Piessen et al., Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1005\u20131020 (2022). https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004","journal-title":"Ann. Oncol."},{"key":"1218_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3322\/caac.21657","volume":"71","author":"SS Joshi","year":"2021","unstructured":"S.S. Joshi, B.D. Badgwell, Current treatment and recent progress in gastric cancer. CA Cancer J. Clin. 71, 264\u2013279 (2021). https:\/\/doi.org\/10.3322\/caac.21657","journal-title":"CA Cancer J. Clin."},{"key":"1218_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","volume":"18","author":"Y Nakamura","year":"2021","unstructured":"Y. Nakamura, A. Kawazoe, F. Lordick, Y.Y. Janjigian, K. Shitara, Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat. Rev. Clin. Oncol. 18, 473\u2013487 (2021). https:\/\/doi.org\/10.1038\/s41571-021-00492-2","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1218_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network, Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513, 202\u2013209 (2014). https:\/\/doi.org\/10.1038\/nature13480","journal-title":"Nature"},{"key":"1218_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"R. Cristescu, J. Lee, M. Nebozhyn, K.M. Kim, J.C. Ting, S.S. Wong et al., Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat. Med. 21, 449\u2013456 (2015). https:\/\/doi.org\/10.1038\/nm.3850","journal-title":"Nat. Med."},{"key":"1218_CR9","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1158\/1078-0432.CCR-16-2211","volume":"23","author":"BH Sohn","year":"2017","unstructured":"B.H. Sohn, J.E. Hwang, H.J. Jang, H.S. Lee, S.C. Oh, J.J. Shim et al., Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin. Cancer Res. 23, 4441\u20134449 (2017). https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2211","journal-title":"Clin. Cancer Res."},{"key":"1218_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Y.J. Bang, Van E. Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki et al., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376, 687\u2013697 (2010). https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"key":"1218_CR11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"K. Shitara, F. Lordick, Y.J. Bang, P. Enzinger, D. Ilson, M.A. Shah et al., Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 401, 1655\u20131668 (2023). https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7","journal-title":"Lancet"},{"key":"1218_CR12","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"M.A. Shah, K. Shitara, J.A. Ajani, Y.J. Bang, P. Enzinger, D. Ilson et al., Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023). https:\/\/doi.org\/10.1038\/s41591-023-02465-7","journal-title":"Nat. Med."},{"key":"1218_CR13","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Z.A. Wainberg, P.C. Enzinger, Y.K. Kang et al., Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 23, 1226\u20131237 (2022)","journal-title":"Lancet Oncol."},{"key":"1218_CR14","unstructured":"Amgen, Amgen announces positive topline Phase 3 results for bemarituzumab in fibroblast growth factor receptor 2b (FGFR2b) positive first-line gastric cancer (Amgen press release, 2025)"},{"key":"1218_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Y.Y. Janjigian, K. Shitara, M. Moehler, M. Garrido, P. Salman, L. Shen et al., First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 398, 27\u201340 (2021). https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"1218_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"S.Y. Rha, D.Y. Oh, P. Ya\u00f1ez, Y. Bai, M.H. Ryu, J. Lee et al., Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181\u20131195 (2023). https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6","journal-title":"Lancet Oncol."},{"key":"1218_CR17","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"F. Pietrantonio, R. Miceli, A. Raimondi, Y.W. Kim, W.K. Kang, R.E. Langley et al., Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J. Clin. Oncol. 37, 3392\u20133400 (2019). https:\/\/doi.org\/10.1200\/JCO.19.01124","journal-title":"J. Clin. Oncol."},{"key":"1218_CR18","unstructured":"Astra Zeneca, IMFINZI\u00ae approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers (Astra Zeneca press release, 2025)"},{"key":"1218_CR19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","volume":"10","author":"R Bai","year":"2020","unstructured":"R. Bai, N. Chen, L. Li, N. Du, L. Bai, Z. Lv et al., Mechanisms of cancer resistance to immunotherapy. Front. Oncol. 10, 1290 (2020). https:\/\/doi.org\/10.3389\/fonc.2020.01290","journal-title":"Front. Oncol."},{"key":"1218_CR20","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.jlb.2025.100288","volume":"7","author":"J Gasparello","year":"2025","unstructured":"J. Gasparello, C. Ceccon, V. Angerilli, T. Comunello, M. Sabbadin, F. D\u2019Almeida Costa et al., Liquid biopsy in gastric cancer: A snapshot of the current state of the art. J. Liq Biopsy. 7, 100288 (2025). https:\/\/doi.org\/10.1016\/j.jlb.2025.100288","journal-title":"J. Liq Biopsy"},{"key":"1218_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-024-01972-6","volume":"23","author":"S Peng","year":"2024","unstructured":"S. Peng, A. Lin, A. Jiang, C. Zhang, J. Zhang, Q. Cheng et al., CTLs heterogeneity and plasticity: implications for cancer immunotherapy. Mol. Cancer. 23, 58 (2024). https:\/\/doi.org\/10.1186\/s12943-024-01972-6","journal-title":"Mol. Cancer"},{"key":"1218_CR22","doi-asserted-by":"publisher","first-page":"9980410","DOI":"10.1155\/2021\/9980410","volume":"2021","author":"JP Nshizirungu","year":"2021","unstructured":"J.P. Nshizirungu, S. Bennis, I. Mellouki, M. Sekal, D.A. Benajah, N. Lahmidani et al., Reproduction of the cancer genome atlas (TCGA) and Asian cancer research group (ACRG) gastric cancer molecular classifications and their association with clinicopathological characteristics and overall survival in Moroccan patients. Dis. Markers. 2021, 9980410 (2021). https:\/\/doi.org\/10.1155\/2021\/9980410","journal-title":"Dis. Markers"},{"key":"1218_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3390\/ijms24010813","volume":"24","author":"M Salati","year":"2023","unstructured":"M. Salati, M. Ghidini, M. Paccagnella, L. Reggiani Bonetti, A. Bocconi, A. Spallanzani et al., Clinical significance of molecular subtypes in western advanced gastric cancer: A real-world multicenter experience. Int. J. Mol. Sci. 24, 813 (2023). https:\/\/doi.org\/10.3390\/ijms24010813","journal-title":"Int. J. Mol. Sci."},{"key":"1218_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000527098","volume":"101","author":"T Toshima","year":"2023","unstructured":"T. Toshima, H. Tanioka, Y. Mori, T. Tanaka, K. Yasui, K. Kimura et al., Genomically stable gastric cancer characterized by hypomethylation in Wnt signal cascade. Oncology. 101, 105\u2013116 (2023). https:\/\/doi.org\/10.1159\/000527098","journal-title":"Oncology"},{"key":"1218_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ng.2984","volume":"46","author":"M Kakiuchi","year":"2014","unstructured":"M. Kakiuchi, T. Nishizawa, H. Ueda, K. Gotoh, A. Tanaka, A. Hayashi et al., Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat. Genet. 46, 583\u2013587 (2014). https:\/\/doi.org\/10.1038\/ng.2984","journal-title":"Nat. Genet."},{"key":"1218_CR26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14712598.2024.2304556","volume":"24","author":"T Ichikawa","year":"2024","unstructured":"T. Ichikawa, Y.Y. Janjigian, The evolving landscape of the tumor microenvironment in gastric cancer and implications for immunotherapy. Expert Opin. Biol. Ther. 24, 15\u201328 (2024)","journal-title":"Expert Opin. Biol. Ther."},{"key":"1218_CR27","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1186\/s12885-024-13236-z","volume":"24","author":"J Brodkin","year":"2024","unstructured":"J. Brodkin, T. Kaprio, J. Hagstr\u00f6m, A. Lepp\u00e4, A. Kokkola, C. Haglund et al., Prognostic effect of immunohistochemically determined molecular subtypes in gastric cancer. BMC Cancer. 24, 1482 (2024). https:\/\/doi.org\/10.1186\/s12885-024-13236-z","journal-title":"BMC Cancer"},{"key":"1218_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2020.09.019","volume":"495","author":"J Yang","year":"2020","unstructured":"J. Yang, Z. Liu, B. Zeng, G. Hu, R. Gan, Epstein-Barr virus-associated gastric cancer: A distinct subtype. Cancer Lett. 495, 191\u2013199 (2020). https:\/\/doi.org\/10.1016\/j.canlet.2020.09.019","journal-title":"Cancer Lett."},{"key":"1218_CR29","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1038\/s41388-021-01743-3","volume":"40","author":"Y Chen","year":"2021","unstructured":"Y. Chen, W.Y. Cheng, H. Shi, S. Huang, H. Chen, D. Liu et al., Classifying gastric cancer using Flora reveals clinically relevant molecular subtypes and highlights LINC01614 as a biomarker for patient prognosis. Oncogene. 40, 2898\u20132909 (2021). https:\/\/doi.org\/10.1038\/s41388-021-01743-3","journal-title":"Oncogene"},{"key":"1218_CR30","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.ctrv.2021.102175","volume":"95","author":"E Puliga","year":"2021","unstructured":"E. Puliga, S. Corso, F. Pietrantonio, S. Giordano, Microsatellite instability in Gastric Cancer: between lights and shadows. Cancer Treat. Rev. 95, 102175 (2021). https:\/\/doi.org\/10.1016\/j.ctrv.2021.102175","journal-title":"Cancer Treat. Rev."},{"key":"1218_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/pin.13427","volume":"74","author":"T Kuwata","year":"2024","unstructured":"T. Kuwata, Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma. Pathol. Int. 74, 301\u2013316 (2024). https:\/\/doi.org\/10.1111\/pin.13427","journal-title":"Pathol. Int."},{"key":"1218_CR32","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.4143\/crt.2024.317","volume":"56","author":"DS Han","year":"2024","unstructured":"D.S. Han, Y. Kwak, S. Lee, S.K. Nam, S.H. Kong, D.J. Park et al., Effector function characteristics of exhausted CD8 + T-cell in microsatellite stable and unstable gastric cancer. Cancer Res. Treat. 56, 1146\u20131163 (2024). https:\/\/doi.org\/10.4143\/crt.2024.317","journal-title":"Cancer Res. Treat."},{"key":"1218_CR33","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.3390\/jcm12144646","volume":"12","author":"Y Sato","year":"2023","unstructured":"Y. Sato, K. Okamoto, Y. Kawano, A. Kasai, T. Kawaguchi, T. Sagawa et al., Novel biomarkers of gastric cancer: current research and future perspectives. J. Clin. Med. 12, 4646 (2023). https:\/\/doi.org\/10.3390\/jcm12144646","journal-title":"J. Clin. Med."},{"key":"1218_CR34","doi-asserted-by":"publisher","first-page":"188549","DOI":"10.1016\/j.bbcan.2021.188549","volume":"1876","author":"Y Zhu","year":"2021","unstructured":"Y. Zhu, X. Zhu, X. Wei, C. Tang, W. Zhang, HER2-targeted therapies in gastric cancer. Biochim. Biophys. Acta Rev. Cancer. 1876, 188549 (2021). https:\/\/doi.org\/10.1016\/j.bbcan.2021.188549","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1218_CR35","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1016\/j.csbj.2020.10.021","volume":"18","author":"Y Ling","year":"2020","unstructured":"Y. Ling, Y. Watanabe, M. Nagahashi, Y. Shimada, H. Ichikawa, T. Wakai et al., Genetic profiling for diffuse type and genomically stable subtypes in gastric cancer. Comput. Struct. Biotechnol. J. 18, 3301\u20133308 (2020). https:\/\/doi.org\/10.1016\/j.csbj.2020.10.021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1218_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.32471\/exp-oncology.2312-8852.vol-44-no-4.18903","volume":"44","author":"YV Dumanskyi","year":"2022","unstructured":"Y.V. Dumanskyi, S.I. Kirkilevskyi, O.M. Sulaeva, V.O. Polyasnyi, A.O. Mashukov, L.A. Kovalevska et al., Impact of tumor molecular phenotype on survival of patients with gastric cancer after radical surgery. Exp. Oncol. 44, 324\u2013326 (2022). https:\/\/doi.org\/10.32471\/exp-oncology.2312-8852.vol-44-no-4.18903","journal-title":"Exp. Oncol."},{"key":"1218_CR37","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/jcm12103391","volume":"12","author":"S Ariga","year":"2023","unstructured":"S. Ariga, History and future of HER2-targeted therapy for advanced gastric cancer. J. Clin. Med. 12, 3391 (2023). https:\/\/doi.org\/10.3390\/jcm12103391","journal-title":"J. Clin. Med."},{"key":"1218_CR38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"J. Yoon, D.Y. Oh, HER2-targeted therapies beyond breast cancer, an update. Nat. Rev. Clin. Oncol. 21, 675\u2013700 (2024). https:\/\/doi.org\/10.1038\/s41571-024-00924-9","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1218_CR39","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s11864-025-01300-0","volume":"26","author":"L He","year":"2025","unstructured":"L. He, B. Liu, Z. Wang, Q. Han, H. Chen, Evolving landscape of HER2-targeted therapies for gastric cancer patients. Curr. Treat. Options Oncol. 26, 260\u2013277 (2025). https:\/\/doi.org\/10.1007\/s11864-025-01300-0","journal-title":"Curr. Treat. Options Oncol."},{"key":"1218_CR40","doi-asserted-by":"publisher","first-page":"217362","DOI":"10.1016\/j.canlet.2024.217362","volume":"611","author":"A Tojjari","year":"2024","unstructured":"A. Tojjari, Y.A. Idrissi, A. Saeed, Emerging targets in gastric and pancreatic cancer: focus on claudin 18.2. Cancer Lett. 611, 217362 (2024). https:\/\/doi.org\/10.1016\/j.canlet.2024.217362","journal-title":"Cancer Lett."},{"key":"1218_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-024-01537-6","volume":"17","author":"Q Zhang","year":"2024","unstructured":"Q. Zhang, Q. Liang, R. Zhang, N. Wang, X. Xiao, J. Shao et al., Identification of SARS-CoV-2-specific T cell and its receptor. J. Hematol. Oncol. 17, 15 (2024). https:\/\/doi.org\/10.1186\/s13045-024-01537-6","journal-title":"J. Hematol. Oncol."},{"key":"1218_CR42","unstructured":"Astellas Pharma Inc, FDA. Approves VYLOY\u2122 (zolbetuximab-clzb) for Treatment of Advanced Gastric and GEJ Cancer, vol. 18 (Press Release, 2024)"},{"key":"1218_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"C.S. Fuchs, J. Tomasek, C.J. Yong, F. Dumitru, R. Passalacqua, C. Goswami et al., Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 383, 31\u201339 (2014). https:\/\/doi.org\/10.1016\/S0140-6736(13)61719-5","journal-title":"Lancet"},{"key":"1218_CR44","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"H. Wilke, K. Muro, Van E. Cutsem, S.C. Oh, G. Bodoky, Y. Shimada et al., Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224\u20131235 (2014). https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6","journal-title":"Lancet Oncol."},{"key":"1218_CR45","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"J. Li, S. Qin, J. Xu, J. Xiong, C. Wu, Y. Bai et al., Randomized, double-blind, placebo-controlled Phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. 34, 1448\u20131454 (2016). https:\/\/doi.org\/10.1200\/JCO.2015.63.5995","journal-title":"J. Clin. Oncol."},{"key":"1218_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10120-015-0537-5","volume":"19","author":"G Roviello","year":"2016","unstructured":"G. Roviello, R. Petrioli, L. Marano, K. Polom, D. Marrelli, A. Perrella et al., Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer. 19, 31\u201341 (2016). https:\/\/doi.org\/10.1007\/s10120-015-0537-5","journal-title":"Gastric Cancer"},{"key":"1218_CR47","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.3390\/curroncol31080321","volume":"31","author":"A Tojjari","year":"2024","unstructured":"A. Tojjari, S. Nagdas, A. Saeed, A. Saeed, Deciphering the FGFR2 code: innovative targets in gastric cancer therapy. Curr. Oncol. 31, 4305\u20134317 (2024). https:\/\/doi.org\/10.3390\/curroncol31080321","journal-title":"Curr. Oncol."},{"key":"1218_CR48","doi-asserted-by":"publisher","first-page":"e0260303","DOI":"10.1371\/journal.pone.0260303","volume":"16","author":"H Harada","year":"2021","unstructured":"H. Harada, Y. Nie, I. Araki, T. Soeno, M. Chuman, M. Washio et al., Haploinsufficiency by minute MutL homolog 1 promoter DNA methylation may represent unique phenotypes of microsatellite instability-gastric carcinogenesis. PLOS One. 16, e0260303 (2021). https:\/\/doi.org\/10.1371\/journal.pone.0260303","journal-title":"PLOS One"},{"key":"1218_CR49","doi-asserted-by":"crossref","unstructured":"A. R. Cozac-Sz\u0151ke, D. A. Cozac, and A. Negovan et al., Immune cell interactions and immune checkpoints in the tumor microenvironment of gastric cancer, Int. J. Mol. Sci. 26, 1156 (2025).","DOI":"10.3390\/ijms26031156"},{"key":"1218_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12916-025-03889-3","volume":"23","author":"Y Xie","year":"2025","unstructured":"Y. Xie, H. Peng, Y. Hu, K. Jia, J. Yuan, D. Liu et al., Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer. BMC Med. 23, 59 (2025). https:\/\/doi.org\/10.1186\/s12916-025-03889-3","journal-title":"BMC Med."},{"key":"1218_CR51","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3089359\/v1","author":"D Duda","year":"2023","unstructured":"D. Duda, S. Dima, A. Sorop, S. Kitahara, N. Setia, M. Chivu-Economescu et al., A tumor microenvironment-based classification of gastric cancer for more effective diagnosis and treatment. Res. Sq. (2023). https:\/\/doi.org\/10.21203\/rs.3.rs-3089359\/v1rs.3.rs-3089359.","journal-title":"Res. Sq"},{"key":"1218_CR52","doi-asserted-by":"publisher","first-page":"1310325","DOI":"10.3389\/fonc.2024.1310325","volume":"14","author":"Y Zhu","year":"2024","unstructured":"Y. Zhu, M. Zhou, C. Li, W. Kong, Y. Hu, Gastric cancer with brain metastasis: from molecular characteristics and treatment. Front. Oncol. 14, 1310325 (2024). https:\/\/doi.org\/10.3389\/fonc.2024.1310325 . (Note: Corresponds to source text describing combination yielding better outcomes)","journal-title":"Front. Oncol."},{"key":"1218_CR53","doi-asserted-by":"publisher","first-page":"917313","DOI":"10.3389\/fonc.2022.917313","volume":"12","author":"Y Zhao","year":"2022","unstructured":"Y. Zhao, Z. Ji, J. Li, S. Zhang, C. Wu, R. Zhang et al., Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients. Front. Oncol. 12, 917313 (2022). https:\/\/doi.org\/10.3389\/fonc.2022.917313","journal-title":"Front. Oncol."},{"key":"1218_CR54","doi-asserted-by":"publisher","first-page":"175883592513464","DOI":"10.1177\/17588359251346423","volume":"17","author":"Y Chen","year":"2025","unstructured":"Y. Chen, Y. Lin, Y. Xu, J. Zhang, S. Chen, S. Ye et al., Immune checkpoint inhibitors improve the efficacy of neoadjuvant chemotherapy in advanced gastric cancer: a retrospective cohort study. Ther. Adv. Med. Oncol. 17, 17588359251346423 (2025). https:\/\/doi.org\/10.1177\/17588359251346423","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1218_CR55","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/cei\/uxac007","volume":"207","author":"S Cen","year":"2022","unstructured":"S. Cen, H. Xu, Z. Liu, R. Zhao, H. Pan, W. Han, Immune microenvironment characteristics and their implications for immune checkpoint inhibitor efficacy in HER2-overexpressing gastric cancer. Clin. Exp. Immunol. 207, 318\u2013328 (2022). https:\/\/doi.org\/10.1093\/cei\/uxac007","journal-title":"Clin. Exp. Immunol."},{"key":"1218_CR56","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41419-025-07385-7","volume":"16","author":"D Luo","year":"2025","unstructured":"D. Luo, J. Zhou, S. Ruan, B. Zhang, H. Zhu, Y. Que et al., Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies. Cell. Death Dis. 16, 75 (2025). https:\/\/doi.org\/10.1038\/s41419-025-07385-7","journal-title":"Cell. Death Dis."},{"key":"1218_CR57","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1186\/s12916-024-03801-5","volume":"22","author":"X Zhang","year":"2024","unstructured":"X. Zhang, X. Dai, A. Liu, M. Sun, L. Cong, J. Liang et al., Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study. BMC Med. 22, 585 (2024). https:\/\/doi.org\/10.1186\/s12916-024-03801-5","journal-title":"BMC Med."},{"key":"1218_CR58","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/14737140.2023.2238896","volume":"23","author":"M Noori","year":"2023","unstructured":"M. Noori, F. Fayyaz, M.R. Zali, D. Bashash, Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for gastric cancer treatment: a systematic review and meta-analysis. Expert Rev. Anticancer Ther. 23, 1029\u20131039 (2023). https:\/\/doi.org\/10.1080\/14737140.2023.2238896","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1218_CR59","doi-asserted-by":"publisher","first-page":"908026","DOI":"10.3389\/fonc.2022.908026","volume":"12","author":"A El Helali","year":"2022","unstructured":"El A. Helali, J. Tao, C.H.L. Wong, W.W.L. Chan, K.C. Mok, W.F. Wu et al., A meta-analysis with systematic review: efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer. Front. Oncol. 12, 908026 (2022). https:\/\/doi.org\/10.3389\/fonc.2022.908026","journal-title":"Front. Oncol."},{"key":"1218_CR60","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.5114\/aoms.2020.97707","volume":"18","author":"W Yi-Wen","year":"2022","unstructured":"W. Yi-Wen, L. Long-Long, L. Ming, L. Hao, H. Kong-Wang, Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer. Arch. Med. Sci. 18, 1297\u20131307 (2022). https:\/\/doi.org\/10.5114\/aoms.2020.97707","journal-title":"Arch. Med. Sci."},{"key":"1218_CR61","doi-asserted-by":"publisher","first-page":"963091","DOI":"10.3389\/fonc.2022.963091","volume":"12","author":"Z Li","year":"2022","unstructured":"Z. Li, M. Song, S. Han, C. Jin, J. Yang, The prognostic role of circulating tumor cells in gastric cancer: a meta-analysis. Front. Oncol. 12, 963091 (2022). https:\/\/doi.org\/10.3389\/fonc.2022.963091","journal-title":"Front. Oncol."},{"key":"1218_CR62","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1007\/s10238-023-01158-2","volume":"23","author":"Q Deng","year":"2023","unstructured":"Q. Deng, B. Jiang, H. Yan, J. Wu, Z. Cao, Circulating tumor cells in gastric cancer: developments and clinical applications. Clin. Exp. Med. 23, 4385\u20134399 (2023). https:\/\/doi.org\/10.1007\/s10238-023-01158-2","journal-title":"Clin. Exp. Med."},{"key":"1218_CR63","doi-asserted-by":"publisher","first-page":"621","DOI":"10.4143\/crt.2024.1222","volume":"57","author":"JH Yun","year":"2025","unstructured":"J.H. Yun, Y.Y. Choi, J.H. Cheong, The current evidence and future direction of adjuvant treatment for gastric cancer in the era of precision medicine. Cancer Res. Treat. 57, 621\u2013634 (2025). https:\/\/doi.org\/10.4143\/crt.2024.1222","journal-title":"Cancer Res. Treat."},{"key":"1218_CR64","doi-asserted-by":"publisher","first-page":"31060","DOI":"10.1038\/s41598-024-82233-w","volume":"14","author":"Z Bai","year":"2024","unstructured":"Z. Bai, H. Wang, J. Han, J. An, Z. Yang, X. Mo, Multiomics integration and machine learning reveal prognostic programmed cell death signatures in gastric cancer. Sci. Rep. 14, 31060 (2024). https:\/\/doi.org\/10.1038\/s41598-024-82233-w","journal-title":"Sci. Rep."},{"issue":"Supplement","key":"1218_CR65","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.4103\/IJPM.IJPM_950_20","volume":"64","author":"I Pandey","year":"2021","unstructured":"I. Pandey, V. Misra, A.T. Pandey, P.W. Ramteke, R. Agrawal, Artificial intelligence technologies empowering identification of novel diagnostic molecular markers in gastric cancer. Indian J. Pathol. Microbiol. 64(Supplement), S63\u2013S68 (2021). https:\/\/doi.org\/10.4103\/IJPM.IJPM_950_20","journal-title":"Indian J. Pathol. Microbiol."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01218-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01218-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01218-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:08:50Z","timestamp":1783094930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01218-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":65,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01218-1","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}